Evaluation of the current trend of nalidixic acid susceptibility in typhoidal salmonellae; a marker of therapeutic failure for the fluoroquinolones

Iranian Journal of Microbiology

Volumn 3, Issue 2, 2011, Pages 80-83

  Abbasi, S ^a   Imtiaz, A ^a   Usman, J ^a   Kaleem, F ^a   Hassan, A ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Nalidixic acid resistance; Therapeutic failure; Typhoid; Typhoidal salmonella

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DISK DIFFUSION; NONHUMAN; PREDICTION; SALMONELLA PARATYPHI; SALMONELLA TYPHI; TREATMENT FAILURE;

SALMONELLA; SALMONELLA PARATYPHI; SALMONELLA TYPHI;

EID: 80053902436     PISSN: 20083289     EISSN: 20084447     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Papagrigorakis MJ, Yapijakis C, Synodinos PN, Baziotopoulou-Valavani E. DNA examination of ancient dental pulp incriminates typhoid fever as a probable cause of the Plague of Athens. Int J Infect Dis 2006; 10: 206-214.
2. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull WHO 2004; 82: 346-353.
3. Ochiai RL, Wang XY, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, et al. Salmonella Paratyphi A rates in Asia. Emerg Infect Dis 2005; 11. ISSN: 1080-6040
4. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002; 347: 1182-84. ISSN: 0028-4793
5. Ahmad R, Mahmood A, Zaidi S. Ciprofloxacin treatment failure in typhoid fever case,Pakistan. East Mediterr Health J 2005; 11:1621-1622.
6. Asna SM, Haq JA, Rahman M. Nalidixic acid-resistant Salmonellaenterica serovar typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 2003; 56: 32-33.
7. Ouabdesselam S, Tankovic J, Soussy CJ. Quinolone resistance mutations in the gyrA gene of clinical isolatesof Salmonella. Microb Drug Resist 1996; 2: 299-302.
8. Hakanen A, Kotilainen P, Jalava J, Sutonen A, Huovinen P. Detection of decrease fluroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999 November; 37: 3572-3577.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 19th informational supplement M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA. 2009.
10. Butt T, Ahmad RN, Salman M, Kazmi SY. Changing trends in drug resistance among typhoid Salmonellae in Rawalpindi, Pakistan. East Mediterr Health J 2005; 11: 1038-1044.
11. Tankhilwala SS, Agarwal G, Jalgaonkar SV. An unusually high occurrence of Salmonella enterica serotype paratyphi A in patients with enteric fever. Ind J Med Res 2003; 117: 10-12.
12. Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302: 859-865.
13. Aggarwal A, Singh A, Oberoi A. A three-year retrospective study on the prevalence, drug susceptibility pattern and phage types of Salmonella enteric subspecies typhi and paratyphi in Christian Medical College and Hospital, Ludhiana, Punjab. J Indian Academy C Med 2007; 8: 32-35.
14. Chandel DS, Chaudhry R, Dhawan B, Pandey A, Dey AB. Drug-resistant Salmonella enterica Serotype Paratyphi A in India. Emer Infec Dis 2000; 6: 420-421.
15. Anjum P, Qureshi A, Parvez M, Zahoor Ul Haq M, Hamid M. Increasing prevalence of multidrug resistant salmonella enterica serotype paratyphiA in patients with enteric fever. Pak J Med Res 2004; 43:56-59.
16. Hannan A, T Butt, Islam SN. First quinolone resistant typhoidal Salmonella. Pak Armed F Med J 1993; 44: 27-30.